Journal of
eISSN: 2373-6453
Submit manuscript...
Mini Review Volume 6 Issue 1
Triple Negative Breast Cancer (TNBC): A Challenge for Current Cancer Therapy
Satish Shilpi, Roshni Shivvedi, Kapil Khatri
Drug Targeting Research Project Laboratory, Department of Pharmaceutics, India
Received: November 29, 2017 | Published: January 3, 2018
Citation: Shilpi S, Shivvedi R, Khatri K (2018) Triple Negative Breast Cancer (TNBC): A Challenge for Current Cancer Therapy. J Hum Virol Retrovirol 6(1): 00189. DOI: 10.15406/jhvrv.2018.06.00189
Abstract
Breast cancer is one of the most common causes of worldwide human deaths. Triple Negative Breast Cancer (TNBC) is advanced cancer does not show immune histochemical expression of estrogens receptors, progesterone receptors or HER2 and it not respond to their respective therapy. It was found that approx 20% of breast cancer is a triple negative. The description of well-defined molecular subtypes of breast cancer, together with the identification of the driving genetic alterations and signalling pathways, has led to chance of the clinical development of a number of successful molecular targeting and therapeutic agents. At present, no suitable treatment option is available for patients with TNBC. This short review presents recent information associated with an improved understanding of the biology of TNBC that has led to development of new chemotherapy drugs, such as platinum compounds, antibodies, siRNA and several targeting agents, including poly (ADP-ribose) polymerase inhibitors, epidermal growth factor receptor (EGFR) inhibitors, angiogenesis inhibitors, vascular endothelial growth factor (VEGFR). Ongoing clinical trials will further define the optimal chemotherapy regimen and most effective targeted therapeutic strategy for TNBC.
Keywords: TNBC, Estrogens, HER2, EGFR inhibitor, Progesterone, Receptor, Chemotherapy, Endothelial, Resistance, Disease, Postmenopausal, Inhibitors, Patients, Hormonal, Clinico-pathologic
©2018 Shilpi, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.